Phibro Animal Health | PAHC - 销售和管理费用

金融业

USD

USD 1.5B

现金及等价物

USD 61.42M

USD 240.42M

USD 935.51M

USD 316.47M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 385.48M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 597.69M

USD 1.47B

USD 27.46M

USD 361.83M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 534.88M

贸易债权人

USD 127.31M

应收帐款人

USD 215.87M

	销售和管理费用	更改		日
Align Technology	USD 462.67M		2.67M	2026-06
ANI Pharmaceuticals	USD 91.66M		18.01M	2026-06
Aurora Cannabis	CAD 41.4M		781K	2026-03
Bristol-Myers Squibb	USD 1.83B		209M	2026-06
Canopy Growth	CAD 31.17M		2.27M	2026-03
Corcept Therapeutics	USD 156.9M		28.85M	2026-06
Eli Lilly	USD 3.43B		496M	2026-06
Henry Schein	USD 831M		22M	2026-06
Idexx Laboratories	USD 288.09M		11.76M	2026-06
Knight Therapeutics	CAD 35.45M		4.43M	2025-12
Merck	USD 2.89B		219M	2026-06
Nektar Therapeutics	USD 11.87M		1.7M	2026-03
Pacira	USD 91.81M		7.93M	2026-06
Phibro Animal Health	USD 78.32M		10.24M	2025-12
Prestige Brands	USD 43.3M		13.02M	2026-06
Supernus Pharmaceuticals	USD 133.64M		15.41M	2026-06
Zoetis	USD 592M		4M	2026-06